MARKET

LIXT

LIXT

Lixte Biotechnology Hldgs Inc
NASDAQ
4.065
+0.075
+1.88%
Opening 14:24 12/16 EST
OPEN
3.970
PREV CLOSE
3.990
HIGH
4.310
LOW
3.900
VOLUME
77.30K
TURNOVER
--
52 WEEK HIGH
6.26
52 WEEK LOW
0.6400
MARKET CAP
23.19M
P/E (TTM)
-3.4569
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at LIXT last week (1208-1212)?
Weekly Report · 1d ago
Lixte Biotechnology Holds Annual Meeting, Approves Key Issues
TipRanks · 5d ago
Lixte Biotechnology Holdings Inc. held annual shareholder meeting
Reuters · 5d ago
Lixte Biotechnology Holdings Inc. Outlines Strategy to Expand Oncology Platform with Complementary Modalities, Advancing PP2A Inhibitor Development and Integrating Radiotherapy Technologies
Reuters · 12/08 13:30
Weekly Report: what happened at LIXT last week (1201-1205)?
Weekly Report · 12/08 09:25
Lixte Biotechnology Holdings Inc. Outlines Strategy to Advance LB-100 Combination Therapy, Strengthen Financial Foundation, and Support Multi-Year Clinical Development
Reuters · 12/03 13:00
Weekly Report: what happened at LIXT last week (1124-1128)?
Weekly Report · 12/01 09:24
Lixte Biotechnology Acquires Liora Technologies for Growth
TipRanks · 11/25 22:26
More
About LIXT
Lixte Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies. The Company’s product pipeline is primarily focused on inhibitors of protein phosphatase 2A, which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. The Company’s inhibitors of protein phosphatases have significant therapeutic potential for a broad range of cancers. It is focused on the clinical development of a specific protein phosphatase inhibitor, LB-100. In addition, lead compounds of the LB-100 series have anti-cancer activity in animal models of glioblastoma multiforme, neuroblastoma, and medulloblastoma, all cancers of neural tissue. Its subsidiary, Liora Technologies Europe Ltd., offers electronically controlled proton therapy systems for treating tumors in various types of cancers.

Webull offers Lixte Biotechnology Holdings Inc stock information, including NASDAQ: LIXT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LIXT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LIXT stock methods without spending real money on the virtual paper trading platform.